Compare Prospect Capital Corporation (PSEC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Prospect Capital Corporation trades at $1.59 (market cap $891.47M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5.5× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 25.15% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PSEC | TVTX | |
|---|---|---|
Market Cap | $891.47M | $4.88B |
Volume | 4,809,352 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $3.05 | $67.52 |
52-Week Low | $1.60 | $26.79 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $2.65B | $5.01B |
Dividend Yield | 25.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.60, down 7.51% with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly earnings have consistently beaten expectations, though the company maintains a modest 25% analyst buy rating amid ongoing dividend distributions of $0.04 monthly.
Outlook remains cautious due to negative cash flow and volatile revenue patterns. The 18%+ dividend yield attracts income investors but carries sustainability risks given declining NAV and portfolio contraction. Analyst consensus leans neutral with 55% hold ratings, reflecting concerns about long-term performance stability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
